Applied Genetic Technologies Corporation has completed enrollment in two phase 1/2 clinical trials of adeno-associated virus-based gene therapies, according to a press release.
One trial evaluating a product candidate for achromatopsia caused by mutations in the CNGB3 gene has completed its dose escalation portion enrollment, while a trial for an X-linked retinitis pigmentosa treatment candidate caused by mutations in the RPGR gene has completed expansion group enrollment.
“Continued success enrolling in all our clinical trials is critical to advancing new and innovative gene therapies
Uncategorized